SLS · SELLAS Life Sciences Group, Inc.

Track SLS — free

$11.26 -0.05 (-0.44%) At close · Oct 8

Russell 2000 member Rebalance outlook locked

Market Cap

$2.27B

201.95M

Volume · Oct 8 4.21M Avg daily vol (3M) 6.53M

Up next

Next earnings call

May 26, 2027 Est · unconfirmed · in 33 wks

Latest filing: 10-Q

filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$32.46M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+92.0%

Year over year · more shares

Price change (1Y)

+495.3%

Trailing year

Short interest

29.2%

Latest settlement · 8.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +41%

above

Price vs 50-day avg −9%

below

RSI (14) 43

neutral

MACD trend Negative

52-week position 70%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −17%

trailing

6-month return +116%

trailing

YTD return +199%

this year

Relative strength +107%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $12 › 200d $8 — 50d above 200d

Institutional flow Distributing

8 of 208 funds reported for Sep 30 · net -46.0K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

29.25% of float · ▲ +2.0% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Fair

Revenue growth −100%

Y/Y

EPS growth +50%

Y/Y

Free cash flow $-28.4M

Balance sheet $5.3M

net cash

Quant / Vol

risk profile

Very High

Volatility 106%

annualized · 1-yr

Max drawdown −36%

past year

ATR 7.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+41% Bullish

Price vs 50-day avg

−9% Bearish

RSI (14)

43 Neutral

MACD trend

Negative Bearish

52-week position

70% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $12 › 200d $8 — 50d above 200d

Institutional flow Distributing

8 of 208 funds reported for Sep 30 · net -46.0K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

29.25% of float · ▲ +2.0% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $11 · 70% Range high $15

vs 200-day avg +41% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SLS SELLAS Life Sciences Group, Inc. this stock	$2.27B	+198.7%	-100.0%	—	29.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$128.16B	+11.0%	+46.2%	29.5	1.9%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.5%
CSLLY Csl Ltd	$60.24B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

209

% held: 51.3%
Reported: 8 of 208
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

124

View

Short & Settlement

Short Interest Rising

Shares short

59.1M

Days to cover: 8.6d
Change: +1.1M sh

View

Short Volume

Short vol %

60%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

990

Value: $11.4K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

53.2%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-26.9M
EPS diluted: $-0.25

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 13

View

Exempt Offerings

Offering

$18.4M

Filed: Mar 29, 2024

View

Earnings & Events

Webcasts

Last webcast

Sep 28, 2026

View

Performance

	5D	20D	120D	MTD	YTD
SLS	-0.6%	-16.5%	+115.7%	-8.5%	+198.7%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	-1.9%	-18.7%	+106.7%	-10.0%	+185.2%

Key facts CIK 1390478 CUSIP 81642T209 13F (30d) 11 filings 11 filers Visit website Investor relations

SLS · SELLAS Life Sciences Group, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance